- Home
- SCYX vs NXB Comparison
SCYX vs NXB Comparison
Compare SCYX & NXB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCYX | NXB |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | |
| Employees | 29 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.0M | 51.1M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SCYX | NXB |
|---|---|---|
| Price | $4.40 | $2.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 77.8K | 48.9K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $608.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $2.02 |
| 52 Week High | $5.62 | $2.57 |
Technical Indicators
Market Signals| Indicator | SCYX | NXB |
|---|---|---|
| Relative Strength Index (RSI) | 68.94 | 57.14 |
| Support Level | $0.67 | N/A |
| Resistance Level | $5.62 | $2.57 |
| Average True Range (ATR) | 0.29 | 0.27 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 70.75 | 21.82 |
Price Performance
Historical ComparisonAbout SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.